Evidence map›Paper›PMID 31750991›Full record

ArticleAngewandte Chemie (International ed. in English)2020

Yttrium-86 Is a Positron Emitting Surrogate of Gadolinium for Noninvasive Quantification of Whole-Body Distribution of Gadolinium-Based Contrast Agents.

Mariane Le Fur, Nicholas J Rotile, Carlos Correcher, Veronica Clavijo Jordan, Alana W Ross, Ciprian Catana, Peter Caravan

Open access · greenAbstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Quantitative in Vivo Molecular MRI.Advanced materials (Deerfield Beach, Fla.) · 2024
    Review
  6. Targeted, Molecular EuropiumJournal of the American Chemical Society · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mariane Le FurThe Athinoula A. Martinos Center for Biomedical Imaging, The Institute for Innovation in Imaging, Massachusetts General Hospital and Harvard Medical School, 149 Thirteenth Street, Charlestown, MA, 02129, USA.
Nicholas J RotileThe Athinoula A. Martinos Center for Biomedical Imaging, The Institute for Innovation in Imaging, Massachusetts General Hospital and Harvard Medical School, 149 Thirteenth Street, Charlestown, MA, 02129, USA.
Carlos CorrecherBruker BioSpin, Preclinical Imaging Division, Eduardo Primo Yúfera 3, 46013, Valencia, Spain.
Veronica Clavijo JordanThe Athinoula A. Martinos Center for Biomedical Imaging, The Institute for Innovation in Imaging, Massachusetts General Hospital and Harvard Medical School, 149 Thirteenth Street, Charlestown, MA, 02129, USA.
Alana W RossThe Athinoula A. Martinos Center for Biomedical Imaging, The Institute for Innovation in Imaging, Massachusetts General Hospital and Harvard Medical School, 149 Thirteenth Street, Charlestown, MA, 02129, USA.
Ciprian CatanaThe Athinoula A. Martinos Center for Biomedical Imaging, The Institute for Innovation in Imaging, Massachusetts General Hospital and Harvard Medical School, 149 Thirteenth Street, Charlestown, MA, 02129, USA.
Peter CaravanThe Athinoula A. Martinos Center for Biomedical Imaging, The Institute for Innovation in Imaging, Massachusetts General Hospital and Harvard Medical School, 149 Thirteenth Street, Charlestown, MA, 02129, USA.ORCID 0000-0002-3179-6537
Massachusetts General Hospital · USBruker (United States) · US

Funding

Stable, High Relaxivity MRI Contrast AgentsR01EB009062 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI CARAVAN, PETER D · 2009 to 2017
$4.9M
MRI-Compatible PET Insert for Small Bore ScannerS10OD023503 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI CARAVAN, PETER D · 2017 to 2017
$600k
Electronics Upgrade for 11.7 TS10OD025234 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI CARAVAN, PETER D · 2018 to 2018
$595k
HPLC-ICP-MS SystemS10OD010650 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI CARAVAN, PETER D · 2013 to 2013
$371k
NIBIB NIH HHS R01 EB009062NIH HHS S10 OD010650NIH HHS S10 OD023503NIH HHS S10 OD025234
6 · The paper itself

Abstract

Gadolinium-based contrast agents (GBCAs) are used to provide diagnostic information in clinical magnetic resonance (MR) examinations. Gadolinium (Gd) has been detected in the brain, bone and skin of patients, months and years following GBCA administration, raising concerns about long term toxicity. Despite increased scrutiny, the concentration, chemical form and fate of the retained gadolinium species remain unknown. Importantly, the whole body biodistribution and organ clearance of GBCAs is poorly understood in humans. Gadolinium lacks suitable isotopes for nuclear imaging. We demonstrate that the yttrium-86 isotope can be used as a gadolinium surrogate. We show that Gd and their analogous Y complexes have similar properties both in solution and in vivo, and that yttrium-86 PET can be used to track the biodistribution of GBCAs over a two-day period.

Indexed as

Contrast MediaGadoliniumHumansMagnetic Resonance ImagingYttrium RadioisotopesContrast MediaGadoliniumYttrium-86Yttrium Radioisotopesgadolinium retentionimaging agentsmagnetic resonance imagingpositron emission tomographyyttrium

Identifiers

PMID31750991
PMCPMC7027945
OpenAlexW2991081588

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.